

ARA-290 Dosing Chart

A peptide derived from erythropoietin, studied for nerve pain and tissue repair without the blood-thickening effects of EPO. Investigational. Commonly discussed doses: 1 mg–8 mg. Research protocols use daily subcutaneous amounts. Figures shown reflect published trial dosing in micrograms. This is investigational data, not a prescribing guide.

thelastpeptide.com · Medically reviewed by Charles Maddix, MSN, APRN, PMHNP-BC · Last reviewed 2026-08-02

FDA STATUS

Not FDA-approved for any use. ARA-290 (cibinetide) is an investigational peptide that has been through human trials but is not approved.

10 mg vial — units to draw (U-100 syringe)

Water added	mg/mL	1 mg	4 mg	8 mg
1 mL	10	10 u	40 u	80 u
2 mL	5	20 u	80 u	—
3 mL	3.33	30 u	—	—

"—" means the draw exceeds one syringe at that concentration. Interactive calculator for any combination: thelastpeptide.com/peptides/ara-290

ARA-290 dose figures are commonly discussed reference information with no approved labeling unless stated above. The Last Peptide is an educational reference and sells nothing. Dosing figures shown here are commonly discussed reference information, not prescriptions or medical advice. Many peptides listed are not FDA-approved. Talk to a licensed clinician before using any peptide.